Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
75 participants
INTERVENTIONAL
2011-01-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo-sham
Placebo-sham twice a week during four weeks
DIMMST
Lidocaine injection
Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
DIMMST
DIMMST
DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).
Twice a week during four weeks
DIMMST
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DIMMST
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disability in the last three months: (defined if they had one or more these limitation in active and routine activities by MPS : (i) interference with work, (ii) enjoyable activities, (iii) responsibilities at home, (iv) relationships, (v) personal goals, (vi) thinking clearly, and problem solving, concentrating, or remembering during the last three months).
* Women
* Age: 19 to 50 years
Exclusion Criteria
Fibromyalgia
Previous surgery on the affected areas
Prior experience with acupuncture
Primary radiculopathy
Current use of psychotropic drugs (ilicits
) Habitual use of anti-inflammatory steroids.
19 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital de Clinicas de Porto Alegre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wolnei Caumo
MD, PhD, Professor and coordinator of Pain & Neuromodulation Lab
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas E Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jose R Goldim, PhD
Role: primary
Jose R Goldim, PhD
Role: primary
José R Goldim, PhD
Role: backup
JOSE GOLDIM, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPS-DIMS
Identifier Type: -
Identifier Source: org_study_id